OUR TEAM
We are highly experienced educators and advisors in building and improving biopharmaceutical value-chains. We relish tackling tough challenges and seeking innovative ways for clients to build their brand reputation and value proposition.
Hedley Rees
Hedley Rees
Managing Consultant and Consultant in Strategic Supply-chain Management
A leading voice on pharmaceutical supply‑chain strategy, grounded in four decades of operational experience.
Hedley Rees is a leading voice on pharmaceutical supply‑chain strategy, arguing that drug availability is national infrastructure—not a procurement problem.
He is the author of Transforming the Pharmaceutical Supply Chain (Wiley, 2025), a board‑level guide that reframes supply‑chain design as a strategic capability and draws on lessons from aerospace, semiconductors, and other high‑reliability sectors. His ideas reach thousands of industry leaders through PharmaFlow’s Path to Prescriptions newsletter on Substack, where he challenges prevailing outsourcing models, exposes CDMO concentration risks, and treats drug shortages as a strategic and security issue.
Hedley’s thinking is grounded in over 40 years of hands‑on experience. He began his career in 1979 at Miles Laboratories (Bridgend) and has since advised global pharma, biotechs, CDMOs, and logistics leaders—including Lonza, Catalent, Oxford BioMedica, Tower Cold Chain, Marken, and UPS Healthcare—on UK and EU advanced manufacturing supply‑chain bids, footprint strategy, and resilience programmes.
He regularly briefs boards, non‑executives, and policymakers on treating biopharma value‑chains as critical national assets, and on designing systems where failure is not an option. He also provides independent expert opinion to legal teams on cases where supply‑chain and manufacturing failures are alleged to have caused patient harm. Hedley is based in Bridgend, Wales, and works with clients across the UK, EU, and US.
Angeliki Kotsianti
Angeliki Kotsianti
Consultant in Medical Governance and Regulatory Strategy
Clinical and regulatory judgement at the point where medical, regulatory, commercial, and legal considerations converge.
Angeliki is a physician‑scientist and molecular pathologist with more than three decades in medicine and science, nineteen of them at Pfizer, where she chaired benefit‑risk decisions and held final medical judgement on the company’s medicines.
Skills and expertise:
- Medical governance and benefit‑risk decision‑making
- Manufacturing, reformulation, recall, and supply decision authority
- CMC and nonclinical development governance
- Medically Necessary Products strategy (built Pfizer’s global framework and pandemic‑era medicine classification)
- EU Critical Medicines Alliance representation, informing the EU Critical Medicines Act
- Evidence governance, including validation and defence of AI‑derived clinical findings
- Oncology outcomes‑prediction machine learning and companion diagnostics
- Co‑founder, Oncolyze Inc. (oncolytic therapy for leukaemia); inventor on eight patents in machine‑learning oncology diagnostics
Angeliki graduated in medicine from Democritus University of Thrace and completed her pathology residency and PhD in molecular pathology at Aristotle University of Thessaloniki, with further training in Switzerland and the United States. At PharmaFlow, she brings the clinical and medical‑governance perspective that complements Hedley’s supply‑chain and manufacturing expertise — particularly for board briefings, resilience reviews, and expert witness engagements. (Pharmaflow Ltd)
Our principles are based on tried and tested approaches to researching and developing innovative new products and services, as practiced by advanced sectors such as semiconductor, aviation, aerospace, electronics and automotive.
Ready to raise the level of your supply‑chain conversation?
Advising pharma, biotech, CDMOs, cold‑chain and logistics leaders — and their legal counsel — across the UK, EU, and US